Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CRHBP | P24387 | 2/20 | 0.74 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA4 | P22748 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | XBP1 | P17861 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821157 | 1.00 | MAPT (0.74) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL13802534 | 0.87 | RAB9A (0.58) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL3151838 | 0.87 | MAPT (0.76) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL4372856 | 0.87 | MAPT (0.76) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL27291251 | 0.87 | MAPT (0.76) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL21620312 | 0.85 | MAPT (0.79) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL3155546 | 0.82 | MAPK1 (0.66) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL3136679 | 0.82 | MAPK1 (1.00) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL7162932 | 0.82 | MAPT (0.73) | MAPTCRHBPCRHR2GAASMN1; SMN2 | |
| SCHEMBL4746925 | 0.82 | MAPT (0.73) | MAPTCRHBPCRHR2GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | claimed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | claimed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | claimed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | MAPT 3584/4885CRHBP 1817/4885CRHR2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.